April/May #195 : New Hep C Drug Sovaldi Approved for Coinfected Use - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Hot & Bothered

Against All Odds

From the Editor

Sexual Healing


Letters-April/May 2014


Dangerous Writing

POZ Planet

Desires to Connect

Porn’s Disappearing Condom Trick!

Antigay Laws Raise HIV Concerns

Does Love Protect Against HIV?

A Military HIV Milestone

Redefining Sex at the CDC


The Last One

Care and Treatment

AIDS Caused by 'Cellular Suicide'

Condomless Sex Rises Among Gay Men

New Hep C Drug Sovaldi Approved for Coinfected Use

The PrEP Report

FDA OKs Switch to Complera

HIV Specific Poison May Complement Antiretrovirals

Research Notes

Prevention: Teens Take Risks, Still Don’t Test

Treatment: Near-Normal Life Expectancy

Cure: Dashed Hopes for Viral Remission

Concerns: Fast-Progressing HIV Strain

SeroZero by GMHC

Editor’s Note

I’m Still Here, Thank God

Research Roundup: Women Over Age 50 and HIV

Releasing Health: Reintegration and Me

What’s Really New About the HIV Epidemic and Young Black Men?

POZ Heroes

Drawing Out the Details

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

April / May 2014

New Hep C Drug Sovaldi Approved for Coinfected Use

by Benjamin Ryan

As expected, the U.S. Food and Drug Administration approved Gilead Sciences’ hotly anticipated new hepatitis C therapy Sovaldi (sofosbuvir) in December. What came as a surprise, however, was the FDA’s approval for the highly effective drug’s use among people coinfected with hep C and HIV. No previous hep C therapy has ever been approved to treat the coinfected population.

“We in the hepatology community are very, very encouraged that coinfected patients were studied vigorously enough and included in the label,” says Andrew Aronsohn, MD, an assistant professor of medicine at the University of Chicago Medical Center. “It’s really making treatment for HIV-coinfected patients a reality, something that is going to be attainable.”

Sovaldi, which must be paired with ribavirin for 12 to 24 weeks of treatment, also offers the potential for those with genotypes 2 or 3 of hep C to receive the first-ever regimen that ditches the notorious weekly injections of interferon and its flu-like side effects. Also, for people who have genotype 1 and who are ineligible to take interferon (a category that some physicians argue includes those who simply do not want to take the drug), physicians may consider prescribing a longer course of treatment with just Sovaldi and ribavirin.

Search: Sovaldi, Hepatitis C, coninfection, ribavirin, FDA

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.